Introduction to Market Access for Pharmaceuticals

Mondher Toumi is M.D. by training, M.Sc. in Biostatistics, and in Biological Sciences (option pharmacology) and Ph.D. in Economic Sciences. Mondher Toumi is Professor of Public Health at Aix-Marseille University. After working for 12 years as Research Manager in the department of pharmacology at the University of Marseille, he joined the Public Health Department in 1993. In 1995 he embraces a carrier in the pharmaceutical industry for 13 years. Toumi was appointed Global Vice President at Lundbeck A/S in charge of health economics, outcome research, pricing, market access, epidemiology, risk management, governmental affairs and competitive intelligence. In 2008, he founded Creativ-Ceutical, an international consulting firm dedicated to support health industries and authorities in strategic decision-making. In February 2009 he was appointed Professor at Lyon I University in the Department of Decision Sciences and Health Policies. The same year, he was appointed Director of the Chair of Public Health and Market Access. He launched the first European University Diploma of Market Access (EMAUD) an international course already followed by almost 350 students. Additionally, he recently created the Market Access Society to promote education, research and scientific activities at the interface of market access, HTA, public health and health economic assessment. He is editor in Chief of the Journal of Market Access and Health Policy (JMAHP) which was just granted PubMed indexation. Toumi is also visiting Professor at Beijing University (Third Hospital). He is a recognized expert in health economics and an authority on market access and risk management. He has more than 250 scientific publications and communications, and has contributed to several books.

Chapter 1: Health as a GoodChapter 2: Decision-Making in Public HealthChapter 3: Definition and ConceptsChapter 4: HTA Decision Analysis frameworkChapter 5: Early HTA AdviceChapter 6: Overview of Market Access AgreementsChapter 7: External Reference PricingChapter 8: Gap between Payers and RegulatorsChapter 9: Early Access ProgramsChapter 10: Market Access of Orphan DrugsChapter 11: Market Access of Vaccines in Developed CountriesChapter 12: FranceChapter 13: GermanyChapter 14: ItalyChapter 15: SpainChapter 16: SwedenChapter 17: United KingdomChapter 18: The United StatesChapter 19: JapanChapter 20: China